Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

Abbott2,000 enrolled

Overview

The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

2,000

Conditions

Hypertension

Interventions

TrandolaprilDRUG

0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Stage 1 or 2 Hypertension Exclusion Criteria: * Uncontrolled diabetes * Subject has a hypersensitivity to ACE inhibitor

Outcomes

Primary Outcomes

Effectiveness of escalating dose regimen of trandolapril in controlling blood pressure

Time frame: 14 weeks

Secondary Outcomes

Changes in blood pressure, safety.

Time frame: 14 and 26 weeks

BP mmHg incremental and absolute change

Time frame: 14 and 26 weeks

Adverse events

Time frame: Throughout 26 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.